Mukul Agarwal

Corporate Officer/Principal en FORTY SEVEN, INC. .

Consumer Services

Health Technology

Perfil

Mukul Agarwal is currently the Vice President of Corporate Development at Forty Seven, Inc. Prior to this, he worked as the Senior Director of Corporate Development and Strategy at Anacor Pharmaceuticals LLC.
From 2016 to 2019, he was the Vice President of Business Development at Revance Therapeutics, Inc. Mr. Agarwal holds a Master's in Business Administration from Carnegie Mellon University, a graduate degree from The Ohio State University, and an undergraduate degree from the Indian Institute of Technology New Delhi.

Cargos activos de Mukul Agarwal

Empresas	Cargo	Inicio
FORTY SEVEN, INC.	Corporate Officer/Principal	-

Todos los cargos activos de Mukul Agarwal

Antiguos cargos conocidos de Mukul Agarwal.

Empresas	Cargo	Fin
REVANCE THERAPEUTICS, INC.	Corporate Officer/Principal	01/03/2019
ANACOR PHARMACEUTICALS INC	Corporate Officer/Principal	-

Ver el detalle de la experiencia de Mukul Agarwal.

Formación de Mukul Agarwal.

Carnegie Mellon University	Masters Business Admin
The Ohio State University	Graduate Degree
Indian Institute of Technology New Delhi	Undergraduate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Mukul Agarwal.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
REVANCE THERAPEUTICS, INC.	Health Technology

Empresas privadas	2
Anacor Pharmaceuticals LLC Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA.	Health Technology
Forty Seven, Inc. Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.	Health Technology